Skip to main content
. 2014 Nov 12;113(3):904–914. doi: 10.1152/jn.00615.2014

Fig. 1.

Fig. 1.

Estradiol benzoate (EB) and the cannabinoid receptor agonist WIN 55,212-2 (WIN) modulate neuronal nitric oxide synthase (nNOS) activation in the mediobasal hypothalamus. A: representative Western blots illustrating the levels of nNOS, phosphorylated nNOS (pnNOS), and the loading control GAPDH in the arcuate nucleus (ARC) and ventromedial nucleus (VMN) microdissected from vehicle-, EB-, and WIN-treated animals. The vertical lines represent demarcations between bands run on different gels. B: composite bar graph illustrating the pnNOS/nNOS ratio determined in ARC and VMN microdissections from vehicle-, EB-, and WIN-treated animals. Bars and vertical lines represent means and SE, respectively. *P < 0.05, values in drug-treated animals that are significantly different (rank-transformed multifactorial ANOVA/LSD; n = 5) from those in vehicle-treated controls.